AlzeCure Pharma (Q3 Review): Clinical phase IIa study in focus - Redeye

Redeye returns with an update following AlzeCure’s Q3 earnings release, which aligned with our expectations. With a reinforced cash position, AlzeCure now prepares to initiate a phase IIa study with NeuroRestore ACD865 in patients with Alzheimer’s disease in 2026. Simultaneously, the company continues its business development efforts regarding all four of its candidates.

Länk till analysen i sin helhet: https://www.redeye.se/research/1139042/alzecure-pharma-q3-review-clinical-phase-iia-study-in-focus?utm_source=finwire&utm_medium=RSS